BioCentury
ARTICLE | Top Story

ViiV to acquire assets from Shionogi JV

October 30, 2012 12:22 AM UTC

ViiV Healthcare Ltd. will acquire exclusive, worldwide rights to develop and commercialize a portfolio of HIV integrase inhibitors from Shionogi-ViiV Healthcare LLC, a JV between ViiV and Shionogi & Co. Ltd. (Tokyo:4507; Osaka:4507). The portfolio includes dolutegravir ( S/GSK1349572), for which worldwide regulatory submissions to treat HIV-1 infection are slated by year end; '572-Trii, a triple combination of dolutegravir plus the marketed nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine in Phase III testing; and S/GSK1265744, which is in Phase IIb testing. Shionogi will own a 10% stake in ViiV and is eligible for dividends, plus royalties in the "high teens" on sales of the portfolio assets. Shionogi will also gain a seat on ViiV's board. The deal is effective Oct. 31. ...